Volume 17 Issue 2, June 2023

The potential of companies developing artificial intelligence (AI)-based tools for drug discovery and development has driven investment and deals with major biopharma companies, but challenges for AI biotechs and biopharma companies are emerging as the field moves beyond the hype towards impact.

POLARIS^qb is slashing the timeframes and costs of drug discovery by using the unique processing power of quantum technology to identify the best lead compounds for drug development.

By integrating artificial intelligence, three-dimensional and multi-organ technology, Quris-AI is developing a ground-breaking clinical-prediction platform with the potential to revolutionize disease modelling and personalized medicine.

Biovista combines augmented and artificial intelligence to drive new possibilities for safer, more-precise medicines.

Perspix Biotech’s roPROTix platform combines artificial intelligence, robotics, and wet biology in a closed-loop feedback system for the discovery of next-generation multi-targeting biological therapeutics.

Taking an innovative approach to applying artificial intelligence (AI) to medical imaging, Quibim is designing predictive panels to enable healthcare providers to improve patient outcomes.

Enveda Biosciences combines machine learning and complex naturally-based libraries of compounds to find potential hits and leads for previously undruggable targets and to uncover novel mechanisms of action.

TeselaGen’s artificial intelligence-enabled operating system for designing, building, and optimizing bio-based products is driving innovation across the biotechnology sector.

Spurred by the pandemic response, a new wave of vaccine technologies is poised to expand a menu of prophylactic options.

Clinical stage company Evaxion Biotech is using artificial intelligence (AI) to simulate the immune system and create predictive models to identify novel targets for vaccines against bacterial and viral diseases and immunotherapies for cancer.

Vaccination saves two to three million lives annually. GSK will continue delivering proven vaccines, expand their availability to populations in need, and create new vaccines to protect against endemic and emerging diseases. To those who possess novel technologies that can innovate vaccine creation, GSK ventures to be your partner of choice.

Achelois developed molecular velcro-based antiviral technology to build next-generation therapeutics to pre-empt emerging pandemic viruses.

The evolution of antifungal resistance is undermining the armamentarium of antifungal therapeutics and threatens novel agents coming through the pipeline. F2G, an antifungal-focused biopharma company, is addressing the need for medicines to treat fungal infections, which is hard but not insurmountable.

SAB Biotherapeutics’ DiversitAb novel drug development platform creates targeted fully human multi-epitope binding immunoglobulins (polyclonal antibodies) without the need for human donors. Its proprietary immunotherapies show promise for treating and preventing infectious diseases and autoimmune and oncological disorders.

Attivare Therapeutics is developing vaccines that offer an amplified humoral and cellular immune response to target infectious diseases with a single-shot option.

Could a mathematical model predict the total value of licensing deals?

The promise of accessing tissues beyond the liver is driving deals between pioneers in the field of nucleic-acid-based drugs and companies developing delivery platforms.

By leveraging the body’s natural RNA-delivery pathways, Sixfold Bioscience is developing a platform that uses modified RNA tags to deliver RNA therapies to desired cell types.

The specialist oncology company helps to develop cutting-edge scientific research into therapeutic interventions for patients in need.

With its innovative modular technology platform and fully integrated organizational approach, DiNAQOR AG is progressing the development and delivery of therapies for devastating genetic diseases of the heart, kidney and other organs.

SMC Laboratories, Inc. (SMC) is a Japan-based contract research organization with a focus on preclinical development in inflammation, fibrosis and oncology.

Pharma companies and regulatory agencies recognize how real-world data can enhance drug development from target identification to clinical trials. BC Platforms provides broad and secure access to this valuable resource in addition to critical tools, interoperable infrastructure, and expertise.

Harnessing its selective organ targeting lipid nanoparticle platform technology, ReCode Therapeutics is facilitating precision delivery of genetic cargos directly to their intended organs and cells.

By combining molecular science and artificial intelligence with years of experience and a world-leading database, Caris Life Sciences aims to revolutionize cancer care and deliver on the promise of precision oncology medicine in partnership with biopharma and industry innovators.

Bio-Techne combines expertise in exosome technologies with experience in the non-invasive liquid biopsy market to create solutions for companion diagnostic development and translational biomarker assay development services for biopharmaceuticals.

Major biopharma companies are inking deals with platform companies to develop molecular glues for targeted protein degradation.

Captor Therapeutics is building a singular pipeline of both next-generation bifunctional degraders and molecular glues based on novel E3 ligases, leveraging academic expertise and industry experience in the United States and Europe, while utilizing significant public and private investment.

InduPro is mapping the cell-surface proteome and designing novel binding proteins to bring cell-surface proteins together to manipulate signaling biology across a range of disease-relevant contexts.

Pennsylvania-based SEED Therapeutics has leveraged the unmatched expertise of its founding team to develop a target-first molecular glue discovery platform.

South Korean biotech Prazer Therapeutics is creating and validating a breakthrough drug discovery and development platform based on targeted protein degradation (TPD) technology to tackle previously undruggable targets in oncology, neuroscience and other therapeutic areas that are not readily addressable with existing TPD approaches.